ArticleScientific reports2026
Proteomic analysis of papillary thyroid carcinoma in the context of Hashimoto's thyroiditis.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
To analyze the proteomic characteristics of papillary thyroid carcinoma in the context of Hashimoto's thyroiditis using mass spectrometry and to screen the differential proteins detected to identify potential biomarkers. Postoperative paraffin specimens were obtained from six patients with Hashimoto's thyroiditis: three with papillary thyroid carcinoma and three with benign nodules. Differentially expressed proteins were identified by qualitative and quantitative analyses using mass spectrometry and high-performance liquid chromatography. Functional enrichment clustering and protein interaction analyses were performed on differentially expressed proteins. Finally, key proteins were screened and immunohistochemical verification was performed on an additional 18 tumor tissue and 17 benign nodule paraffin sections. A total of 72 upregulated and 21 downregulated differentially expressed proteins were identified. THBS2 and COL12A1 were selected using bioinformatics analysis. Immunohistochemical analysis indicated that COL12A1 is a promising candidate as a specific tumor marker worthy of further investigation. The proteins were differentially expressed in patients with Hashimoto's thyroiditis with papillary thyroid carcinoma compared to those with benign nodules. COL12A1, as a key molecule with potential differential diagnostic value, provides a promising target for future research and validation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.